ADVANCES IN SYSTEMIC TREATMENT OF MALIGNANT-MELANOMA

被引:27
作者
AAPRO, MS
机构
关键词
D O I
10.1016/S0959-8049(05)80164-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This paper reviews recent developments in the systemic treatment of advanced malignant melanoma. In the introduction emphasis is given to prevention and early detection of this disease. Metastatic malignant melanoma patients have a median survival of less than 1 year in the most favourable situation. Adjuvant chemotherapeutic treatment after initial surgery has not had an impact on prognosis, while immunological manipulations with interferon alfa or other agents may prove beneficial after primary surgery. In advanced disease which cannot be palliated by surgery, many approaches are under investigation. Modulation of the patient's immune response can be achieved with vaccines, monoclonal antibodies, interleukin-2 and interferons, as single agents or in combination between themselves or with peripheral blood mononuclear cells or with tumour infiltrating lymphocytes or even with chemotherapy. Immunological approaches yield a 20-30% response rate, with some possibly long-term responses. Chemotherapeutic agents have a 10-30% response rate, which is usually of short duration. Combinations of chemotherapeutic agents can increase the response rate to 50%, but an impact on ultimate survival seems unlikely. Randomised studies have shown that modulation of chemotherapy with interferon or tamoxifen improves response rates. Clinicians should be encouraged to enter their patients with malignant melanoma in therapeutic trials.
引用
收藏
页码:613 / 617
页数:5
相关论文
共 51 条
[1]   SEQUENTIAL ADMINISTRATION OF DACARBAZINE AND FOTEMUSTINE IN PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA - AN EFFECTIVE COMBINATION WITH UNEXPECTED TOXICITY [J].
AAMDAL, S ;
GERARD, B ;
BOHMAN, T ;
DINCALCI, M .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :447-450
[2]  
AAPRO MS, 1983, CANCER CHEMOTH PHARM, V10, P161
[3]  
AAPRO MS, 1986, 8TH P EUR SOC MED ON
[4]   FOTEMUSTINE PLUS DACARBAZINE FOR MALIGNANT-MELANOMA [J].
AVRIL, MF ;
BONNETERRE, J ;
CUPISSOL, D ;
GROB, JJ ;
KALIS, B ;
FUMOLEAU, P ;
KERBRAT, P ;
ISRAEL, L ;
FARGEOT, P ;
LAMBERT, D ;
DELAUNAY, M ;
DRENO, B ;
VILMER, C ;
BIZZARI, JP ;
COUR, V .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) :1807-1811
[5]  
Balch CM, 1985, CUTANEOUS MELANOMA C, P321
[6]  
BARR MH, 1990, J CLIN ONCOL, V8, P1138
[7]  
BERD D, 1991, P AN M AM SOC CLIN, V10, P291
[8]   FOTEMUSTINE PLUS DACARBAZINE IN ADVANCED STAGE .3. MALIGNANT-MELANOMA [J].
BINDER, M ;
WINKLER, A ;
DORFFNER, R ;
GLEBOWSKI, E ;
WOLFF, K ;
PEHAMBERGER, H .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (11) :1814-1816
[9]  
BUZAID AC, 1992, P AM SOC CLIN ONCOL, V11, P347
[10]   MULTICENTER PHASE-II TRIAL OF THE SINGLE AGENT FOTEMUSTINE IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA [J].
CALABRESI, F ;
AAPRO, M ;
BECQUART, D ;
DIRIX, L ;
WILS, J ;
ARDIZZONI, A ;
GERARD, B .
ANNALS OF ONCOLOGY, 1991, 2 (05) :377-378